Business
Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in Canada
Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced an expansion of its partnership with Intas Pharmaceuticals for BAT2506, a proposed golimumab biosimilar, through an exclusive commercialization and license agreement for Canada.
About this update from Bio-thera Solutions, Ltd. Class A
[{"type":"text","content":"GUANGZHOU, China, Oct. 9, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced an expansion of its partnership with Intas Pharmaceuticals for BAT2506, a proposed golimumab biosimilar, through an exclusive commercialization and license agreement for Canada.","length":386,"tagName":"p"},{"type":"image","alt":"Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of America","displaySize":"","headline":null,"caption":"Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of America","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":164,"url":"https://media.zenfs.com/en/prnewswire.com/97eff2c03b2e377349e210f37f72da90"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/._uVffpqnA8T_fJwO4U89Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/97eff2c03b2e377349e210f37f72da90","width":400,"height":164}},"href":"https://mma.prnewswire.com/media/2792510/Bio_Thera_and_Intas_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"BAT2506 is a proposed golimumab biosimilar developed by Bio-Thera. Golimumab is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF-), a pro-inflammatory molecule. Binding of golimumab to TNF- results in reductions in C-reactive protein (CRP), Interleukin 6 (IL-6), Intercellular Adhesion Molecule 1 (ICAM-1), Matrix Metalloproteinase 3 (MMP-3), and Vascular Endothelial Growth Factor (VEGF), all inflammatory markers. The reference medicine golimumab has been approved in the Canada for several indications, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.","length":638,"tagName":"p"},{"type":"text","content":""We are pleased to expand our partnership with Accord for BAT2506 by adding Canadian commercialization rights to the partnership," said Bert Thomas, Senior Vice President of Business Development at Bio-Thera. "...